BOSTON, Dec. 1, 2023
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company focused on the
transformation of cardiometabolic diseases, today
announced that Hyung Heon Kim,
President and Chief Executive Officer, Marshall H. Woodworth, Acting Chief Financial
Officer and Robert Homolka, Senior
Vice President of Clinical Operations, will present a company
overview, including updates on the company's promising
cardiometabolic assets, DA-1241, in development as a treatment for
NASH and DA-1726, in development for the treatment of obesity, at
the following investor conferences in December:
- December 7: Investor Summit
Virtual Conference. Mr. Kim, Mr. Woodworth and Mr.
Homolka will present at 11:00 am ET
at this virtual conference.
- December 14: Life Science
Virtual Investor Forum. Mr. Kim, Mr. Woodworth and Mr. Homolka
will present at this virtual conference at 11:00 am ET and will be available for virtual
one-on-one meetings during the event. Interested investors can
register through the Life Science Virtual Investor Forum platform:
https://www.virtualinvestorconferences.com/events/event-details/life-science-investor-forum-1
To schedule a meeting outside of either conference please
contact Michael Miller at
mmiller@rxir.com.
A live webcast of both presentations will be available on the
Event Calendar page of the NeuroBo website at:
https://www.neurobopharma.com/events-presentations/event-calendar.
An archived replay of both conferences will be available on the
company's website after the conference.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is a clinical-stage biotechnology company focused on the
transformation of cardiometabolic diseases. The company is
currently developing DA-1241 for the treatment of Non-Alcoholic
Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM), and is
developing DA-1726 for the treatment of obesity. DA-1241 is a novel
G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the
release of key gut peptides GLP-1, GIP, and PYY. In preclinical
studies, DA-1241 demonstrated positive effect on liver
inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control. DA-1726 is a
novel oxyntomodulin (OXM) analogue that acts as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists. For more
information, please visit www.neurobopharma.com.
Forward Looking Statements
Certain statements in this
release may be considered forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements about the closing of the
offering of securities. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risks associated with our ability to execute on our commercial
strategy, the timeline for regulatory submissions, regulatory steps
and potential regulatory approval of our current and future product
candidates, the ability to realize the benefits of the license
agreement with Dong-A ST Co. Ltd., including the impact on future
financial and operating results of NeuroBo; the ability to
integrate the new product candidates into NeuroBo's business in a
timely and cost-efficient manner; the cooperation of our contract
manufacturers, clinical study partners and others involved in the
development of our current and future product candidates; our
ability to initiate and complete clinical trials on a timely basis;
our ability to recruit subjects for our clinical trials; receiving
results from our clinical trials that are consistent with the
results of pre-clinical and previous clinical trials; costs related
to the license agreement, known and unknown, including costs of any
litigation or regulatory actions relating to the license agreement;
changes in applicable laws or regulations; effects of changes to
NeuroBo's stock price on the terms of the license agreement and any
future fundraising; and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak only as
of the date when made. NeuroBo does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Contacts:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Interim Chief Financial Officer
+1-919-749-8748
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-to-participate-in-investor-conferences-in-december-302003051.html
SOURCE NeuroBo Pharmaceuticals, Inc.